Erasmus MC, Rotterdam, The Netherlands.
Semin Hematol. 2012 Jul;49(3):249-57. doi: 10.1053/j.seminhematol.2012.04.001.
Introduction of the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals, The Takeda Oncology Company, Cambridge, MA) has substantially improved outcomes for patients with multiple myeloma (MM), and has become one of the cornerstones of current anti-myeloma treatment regimens. However, with the introduction of bortezomib it has become clear that peripheral neuropathy (PN) is one of the most frequent, potentially disabling, nonhematologic complications of bortezomib, often requiring dose modification or discontinuation, with a potential negative impact on clinical endpoints and quality of life. To find a balance between maximal benefit of bortezomib treatment, while maintaining quality of life, it is necessary to minimize toxicity. Here, we discuss all aspects of bortezomib-induced peripheral neuropathy (BiPN), and elaborate on the mechanisms underlying the development of BiPN.
蛋白酶体抑制剂硼替佐米（万珂，千禧制药，武田肿瘤公司，马萨诸塞州剑桥）的应用极大地改善了多发性骨髓瘤（MM）患者的预后，已成为目前抗骨髓瘤治疗方案的基石之一。然而，硼替佐米的应用也使其外周神经病变（PN）成为其最常见的、潜在致残的、非血液学并发症之一，常需要调整剂量或停药，从而对临床终点和生活质量产生潜在的负面影响。为了在最大限度地发挥硼替佐米治疗作用的同时，维持生活质量，需要将毒性降到最低。在此，我们讨论了硼替佐米诱导的外周神经病变（BiPN）的各个方面，并详细阐述了 BiPN 发生的机制。
